Baseline characteristics and effects of ten years of growth hormone (GH) replacement therapy in adults previously treated with pituitary irradiation.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

In this prospective, single-centre, open-label study, the effects of 10-year GH replacement were determined in 18 GHD adults that had previously received conventional external fractionated pituitary irradiation therapy (IRR group) and 18 non-irradiated GHD patients (non-IRR group).

All patients had adult onset disease and complete deficiency of anterior pituitary hormones and both groups were comparable in terms of age, gender, body mass index (BMI), and waist:hip ratio.

Why It Was Studied

Little is known of the importance of previous irradiation therapy for baseline characteristics and responsiveness to GH replacement in GH deficient (GHD) adults.

Who Took Part

The abstract describes 18 adults taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as open-label.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the adults and staff both knew the treatment.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Case-Control Studies, Combined Modality Therapy, Glucose, Hormone Replacement Therapy, Human Growth Hormone and Hypopituitarism.

Author keywords: Body composition, Bone mass, Glucose homeostasis, Growth hormone deficiency, Pituitary irradiation and Serum lipid pattern.

What This Means in Plain Language

The paper is an open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.